Argipressin (vasopressin) — what the antidiuretic hormone does in acute care
8 min read · Uplevel editorial
The patient's blood pressure has been falling for hours. The ICU team has given norepinephrine, then more norepinephrine, then more again. The vasopressors are doing less than they should. At some point in that sequence, the intensivist reaches for a different molecule — one that works through a different receptor pathway entirely, one that the body normally makes itself, one that has been sitting in the endocrine system since before mammals had an immune response evolved enough to produce septic shock. Vasopressin. The decision to add it to the norepinephrine drip isn't dramatic; it happens in a sentence in the order set. But the pharmacology behind that decision reaches back to some of the most fundamental biology of fluid and pressure regulation in vertebrates.
Argipressin is the synthetic form of arginine vasopressin, abbreviated AVP. The endogenous molecule is a nine-amino-acid peptide — a nonapeptide — produced in the hypothalamus, specifically in the supraoptic and paraventricular nuclei, and stored and released from the posterior pituitary. The name encodes two functions: vaso, for its effects on blood vessels, and pressin, for the pressure it creates, and then the earlier name antidiuretic hormone, ADH, for its primary day-to-day role in water conservation. Both functions are real, both are clinically relevant, and they operate through different receptor subtypes in different tissues.
The daily job of endogenous AVP is water balance. When plasma osmolality rises — when the blood becomes more concentrated, whether from dehydration or a salty meal or exercise — osmoreceptors in the hypothalamus detect the shift and trigger AVP release from the posterior pituitary. AVP travels in the bloodstream to the kidney, specifically to the collecting ducts of the nephron, where it binds V2 receptors. V2 receptor activation triggers a cascade that inserts aquaporin-2 water channels into the luminal membrane of the collecting duct cells. Water that would otherwise be lost in urine passes back across those channels into the bloodstream. The urine becomes concentrated. Plasma osmolality falls back toward normal. This is happening constantly, in response to small fluctuations in hydration status, as one of the body's most precise homeostatic feedback loops.
Volume depletion also triggers AVP release — low blood pressure and low circulating volume are sensed by baroreceptors in the great vessels and atria, and those signals reach the hypothalamus through pathways that augment AVP release independent of osmolality. This makes physiological sense: if blood volume is critically low, conserving water is one of the fastest tools available. The osmolality signal is sensitive; the volume signal is coarser but also triggers AVP release at lower plasma concentrations than osmolality alone would require.
The vascular effect of vasopressin operates through a separate receptor — V1a, found on vascular smooth muscle cells. V1a activation causes vasoconstriction: blood vessels narrow, peripheral resistance rises, blood pressure climbs. At physiological concentrations, this effect is modest. At pharmacological doses, it's substantial and clinically useful. In vasodilatory shock — the hemodynamic pattern in septic shock and distributive shock states — blood vessels dilate inappropriately and blood pressure falls despite adequate or elevated cardiac output. Catecholamines like norepinephrine act primarily on alpha-adrenergic receptors to cause vasoconstriction, and they're first-line. But in severe vasodilatory shock, endogenous vasopressin levels are often inappropriately low — the posterior pituitary has released its stored supply and can't synthesize more quickly enough — creating what some researchers have described as a relative vasopressin deficiency. Exogenous vasopressin, administered at low fixed doses (typically 0.03 to 0.04 units per minute as an intravenous infusion in adult ICU patients), restores some of this deficit and adds vasoconstriction through a receptor pathway that remains responsive when the adrenergic receptors are becoming saturated or downregulated from catecholamine excess.
The landmark clinical trial in this space, the VASST trial, examined whether adding vasopressin to norepinephrine infusion in septic shock improved outcomes compared to higher-dose norepinephrine alone. The overall results showed no significant mortality difference in the full population. But a pre-specified subgroup analysis suggested a possible benefit in patients with less severe shock — those requiring lower baseline norepinephrine doses — a finding that has influenced how vasopressin is used in practice even while the headline result was neutral. Subsequent trials, including VANISH, have continued to define the role of vasopressin in septic shock without definitively settling all questions. The current state of evidence supports vasopressin as a reasonable catecholamine-sparing agent, useful particularly in patients where reducing norepinephrine dose matters — which it does, because catecholamines at high doses carry their own toxicity profile.
The second major clinical use of exogenous vasopressin is in central diabetes insipidus — a condition that is essentially the opposite of vasopressin excess. In central DI, the posterior pituitary fails to produce or release adequate AVP: the hypothalamic nuclei may have been damaged by a tumor, neurosurgery, head trauma, or autoimmune destruction, or the condition may be idiopathic. Without AVP, the V2 receptors in the renal collecting duct aren't activated, aquaporin channels don't insert, and water pours out in the urine. Patients produce enormous urine volumes — liters per hour in severe cases — and must drink correspondingly to avoid dangerous hypernatremia. Left untreated, central DI produces severe dehydration and electrolyte crisis rapidly. The treatment is hormone replacement: desmopressin (DDAVP), a synthetic analog of vasopressin with selective V2 activity and no meaningful V1 vasoconstriction, is far more commonly used for this indication because of its renal selectivity and long duration of action. But argipressin itself is FDA-approved for diabetes insipidus, and it's used intravenously in acute hospital settings where rapid, titratable control of urine output is needed.
A third application is variceal bleeding — hemorrhage from the esophageal or gastric varices that develop in portal hypertension from cirrhosis. Vasopressin's vasoconstriction extends to the splanchnic vasculature, the blood vessels supplying the gastrointestinal tract, and this splanchnic vasoconstriction reduces portal venous pressure and can slow or stop variceal hemorrhage. Vasopressin used to be the primary pharmacological tool in this setting. It's largely been displaced by terlipressin (a prodrug analog) in countries where terlipressin is available, and by octreotide in the United States, but vasopressin remains in the toolkit.
The broader significance of vasopressin in the peptide landscape is what it illustrates about how much physiological control sits in small molecules. A nine-amino-acid peptide — shorter than the sequences that will appear in most peptide research and clinical discussions — governs water balance in the kidney, vascular tone in peripheral circulation, and splanchnic hemodynamics, all through two receptor subtypes with distinct intracellular signaling. The same compound that determines how concentrated your urine is on a normal Tuesday morning is the compound that ICU physicians reach for in life-threatening hemodynamic collapse. That range of action from a nonapeptide is worth pausing on.
Vasopressin is not a compound that moves through consumer channels or compounding pharmacies in the way that other peptides do. Its use is almost entirely intravenous and inpatient, in contexts where close hemodynamic monitoring is possible and necessary. The doses used in shock management — fractions of a unit per minute — are far from what the body produces physiologically and require titration by experienced clinicians against real-time blood pressure data. It's included in any serious treatment of the endocrine peptide landscape not because it's a compound people are investigating outside of clinical settings, but because understanding what it does illuminates how the posterior pituitary peptides function and why peptide-based hormonal signals carry such outsized effects relative to their molecular size.
The posterior pituitary's other main product, oxytocin, is AVP's close structural neighbor — they differ by only two amino acids — and occupies an entirely different territory of function involving social bonding, uterine contraction, and lactation. That proximity, structurally so close and functionally so distinct, is part of what makes the peptide hormone systems interesting: small changes in sequence produce enormous divergence in receptor binding, tissue distribution, and physiological effect. Vasopressin's story — from osmoregulation in the kidney to shock management in the ICU to the neurobiology of social behavior, where AVP also has emerging research roles — is a compressed map of how much territory a single peptide can occupy when the receptor systems that read it are diverse enough.
Frequently asked